With the exception of N-acetylgalactosamine (GalNAc), which mediates liver targeting, there are no safe and effective means of delivering oligonucleotide drugs to other relevant target cells and ...
The GalNAc platform is made up of two approaches ... Both STP705 and STP707 are made of two siRNA oligonucleotides that hit transforming growth factor beta 1 (TGF-β1) and cyclooxygenase 2 ...
The results come from the phase 1b/2a RestorAATion-2 study of WVE-006, a GalNAc-conjugated oligonucleotide that is designed to correct a mutation in mRNA associated with AATD that prevents ...
Hosted on MSN1mon
Goldman Sachs Initiates Coverage of Silence Therapeutics plc - Depositary Receipt () (SLN) with Sell RecommendationSilence's proprietary messenger RNAi GOLDâ„¢ (GalNAc Oligonucleotide Discovery) Platform can be used to create siRNAs that precisely target and silence disease-associated genes in the liver ...
The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. Receive News ...
WVE-007 is a GalNAc-conjugated small interfering RNA ... clinical development and uses Wave’s best-in-class proprietary oligonucleotide chemistry. INLIGHT is an ongoing, first-in-human, placebo ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback